Foghorn Therapeutics stock rating cut to Hold by TD Cowen on trial halt
TD Cowen downgraded Foghorn Therapeutics (FHTX) to Hold from Buy after it and Eli Lilly halted FHD-909's development. The stock fell to $2.92, down 33.89% YTD. Foghorn plans to cut 40% of its workforce and focus on preclinical programs, extending its cash runway. Analysts have mixed views on its valuation and future prospects.
How this was made
The 30-second read
Why it matters
The trial halt removes the only near‑term revenue catalyst, increasing reliance on future pre‑clinical assets and likely prompting a share price decline.
Market read
The downgrade and trial termination constitute fresh, material news for FHTX, likely driving short‑term sell pressure.
What to watch
Potential partnership or licensing deals for the EP300 program could mitigate cash‑runway concerns.
Background
Foghorn Therapeutics announced a 40% workforce reduction and a shift to wholly owned programs after the Eli Lilly collaboration ended.
Ticker impact
TD Cowen downgraded Foghorn Therapeutics to Hold and announced the halt of the FHD-909 trial collaboration with Eli Lilly, removing the company's only clinical‑stage asset.
downward pressure as investors price in the loss of the clinical asset and need for additional capital.
Analyst downgrade combined with a concrete trial termination is a fresh, material catalyst for a micro‑cap biotech.
Market effects
Biotech sector may see heightened scrutiny on early‑stage programs after this setback.
US biotech investors likely to reassess risk exposure to pre‑clinical pipelines.
Limited to investors tracking small‑cap biotech; no broad market effect.
Counterpoint
If the remaining pipeline shows strong pre‑clinical data, the stock could be undervalued despite the downgrade.
Key entities
- companyFoghorn Therapeutics
Biotech firm developing epigenetic therapies.
- companyEli Lilly
Pharmaceutical partner that ended the collaboration.
- analystTD Cowen
Research firm that downgraded Foghorn to Hold.